血液科

订阅

MedSci主页 / 所有栏目 / 血液科

Blood：14-3-3ζ-c-Src-整合素-β3复合物对血小板激活至关重要！

2020-07-02 MedSci原创 MedSci原创

血小板激活β-整合素14-3-3ζc-Src14-3-3ζ-c-Src-整合素-β3复合物
关注

在血小板激活过程中，14-3-3ζ、c-Src和 integrin-β3形成14-3-3ζ-c-Src-integrin-β3复合物；该复合物干扰消除可在不引起出血的情况下抑制血栓形成。

几个适配器分子与β-整合素的胞内尾段结合，促进双向信号传导，这在血栓形成和止血中至关重要。在空间或时间上干扰整合素-适配器相互作用，以抑制血栓形成，且不影响止血是开发安全抗血栓形成剂的有吸引力的策略。

本研究首次报道在血小板激活过程中，会形成14-3-3ζ-c-Src-integrin（整合素）-β3复合物。14-3-3ζ-c-Src相互作用是由14-3-3ζ上的上清蛋白片段(PE16)和c-Src上的SH2结构域介导的，而14-3-3ζ-整合素-β3的相互作用是由14-3-3ζ上的eskvfylkmkgdyyrYL片段（EL17）和整合素-β3胞内尾段上的keatstf片段（KF7）介导的。

EL17模体抑制剂或FK7肽可干扰14-3-3ζ-c-Src-整合素-β3复合物的形成，选择性抑制β3的细胞外-内信号传导，且不影响整合素-纤维蛋白原的相互作用，从而抑制血栓形成而不引起明显出血。

本研究表征了血小板中既往未知的14-3-3ζ-c-Src-整合素-β3复合物，并为开发安全有效的抗血栓形成疗法提供了新的策略。

原始出处：

Chuanbin Shen，et al. 14-3-3ζ-c-Src-integrin-β3 complex is vital for platelet activation. Blood. June 25，2020.

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1910660, encodeId=79e2191066036, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Feb 03 13:13:41 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668779, encodeId=c8b01668e79b0, content=<a href='/topic/show?id=2ef9166e565' target=_blank style='color:#2F92EE;'>#SRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16675, encryptionId=2ef9166e565, topicName=SRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7c26414300, createdName=zhangxingru, createdTime=Fri Feb 05 00:13:41 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459480, encodeId=23cf1459480cb, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 04 06:13:41 CST 2020, time=2020-07-04, status=1, ipAttribution=)]
    2021-02-03 yang0210

    #复合物#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1910660, encodeId=79e2191066036, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Feb 03 13:13:41 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668779, encodeId=c8b01668e79b0, content=<a href='/topic/show?id=2ef9166e565' target=_blank style='color:#2F92EE;'>#SRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16675, encryptionId=2ef9166e565, topicName=SRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7c26414300, createdName=zhangxingru, createdTime=Fri Feb 05 00:13:41 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459480, encodeId=23cf1459480cb, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 04 06:13:41 CST 2020, time=2020-07-04, status=1, ipAttribution=)]
    2021-02-05 zhangxingru

    #SRC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1910660, encodeId=79e2191066036, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Feb 03 13:13:41 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668779, encodeId=c8b01668e79b0, content=<a href='/topic/show?id=2ef9166e565' target=_blank style='color:#2F92EE;'>#SRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16675, encryptionId=2ef9166e565, topicName=SRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7c26414300, createdName=zhangxingru, createdTime=Fri Feb 05 00:13:41 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459480, encodeId=23cf1459480cb, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 04 06:13:41 CST 2020, time=2020-07-04, status=1, ipAttribution=)]
    2020-07-04 智智灵药

    #整合素#

    0